A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

PHASE3CompletedINTERVENTIONAL

Enrollment

623

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

July 3, 2024

Study Completion Date

October 12, 2024

Conditions

T2DMType 2 Diabetes Mellitus

Interventions

DRUG

Ecnoglutide high dosage

Administered subcutaneously

DRUG

Ecnoglutide low dosage

Administered subcutaneously

DRUG

Dulaglutide

Administered subcutaneously

DRUG

Metformin

Administered orally

Trial Locations (1)

ZHONGSHAN Hospital, Shanghai

All Listed Sponsors

lead

Hangzhou Sciwind Biosciences Co., Ltd.

INDUSTRY